Associated Genetic Biomarkers
NCI Definition: A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma. 
Sarcomas most frequently harbor alterations in TP53, KIT, CDKN2A, RB1, and CDKN2B .
TP53 Mutation, KIT Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, and KIT Exon 11 Mutation are the most common alterations in sarcoma .
There are 48 clinical trials for sarcoma, of which 38 are open and 10 are completed or closed. Of the trials that contain sarcoma as an inclusion criterion, 1 is early phase 1 (1 open), 21 are phase 1 (14 open), 10 are phase 1/phase 2 (9 open), 14 are phase 2 (12 open), and 2 are no phase specified (2 open).
CTAG1A, CTAG1B, and ABL2 are the most frequent gene inclusion criteria for sarcoma clinical trials .
Pembrolizumab, nivolumab, and cyclophosphamide are the most common interventions in sarcoma clinical trials.
Significant Genes in Sarcoma
ACVR1B is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ACVR1B status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) .
ERBB2 is altered in 1.0% of sarcoma patients .
ERBB2 is an inclusion eligibility criterion in 8 clinical trials for sarcoma, of which 5 are open and 3 are closed. Of the trials that contain ERBB2 status and sarcoma as inclusion criteria, 5 are phase 1 (3 open) and 3 are phase 1/phase 2 (2 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.